Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
https://thestreetreports.com/nasdaq-30s-vivs-...tocks-now/
August 25, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm Holdings, Inc. (NASDAQ: RIME) and Xiao-I Corporation (NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology drive trading interest.
VivoSim Labs (NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum
VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention following a research report highlighting its AI-powered drug toxicity platform and growing FDA momentum behind human-relevant New Approach Methodologies (NAMs). The company’s NAMkind™ 3D human liver and intestinal tissue models have reported approximately 91% predictive accuracy for liver toxicity and up to 96% accuracy predicting drug-induced diarrhea, while commercialization is expanding through initial China contracts and APAC distribution relationships.
VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business and recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested inflammatory bowel disease program. VivoSim has stated it remains eligible for up to an additional $45 million in potential milestone payments if specified development and commercial milestones are achieved.
IGC Pharma (NYSE: IGC) — Alzheimer’s Catalyst Approaches
IGC Pharma, Inc. (NYSE: IGC) is approaching a potentially important Alzheimer’s disease clinical catalyst after reporting Q2 2026 results that beat Street estimates and advancing its Phase 2 IGC-AD1 Alzheimer’s trial toward enrollment completion, with topline results expected in Q4 2026.
The company is also expanding its AI-enabled drug discovery capabilities. Management recently converted approximately $1.15 million of company obligations into more than 4.27 million IGC shares at $0.27 per share. Investor interest has strengthened, with shares moving from approximately $0.245 to as high as $0.308 during August, representing a roughly 25.7% increase, accompanied by elevated trading volume.
Algorhythm Holdings (NASDAQ: RIME) — Strategic Alternatives for SemiCab AI Logistics
Algorhythm Holdings, Inc. (NASDAQ: RIME) is an AI technology company whose SemiCab platform uses artificial intelligence to optimize freight networks, reduce empty truck miles, lower transportation costs and improve logistics efficiency for shippers and carriers.
Adding a new potential catalyst, Algorhythm announced on August 25, 2026 that it is pursuing a potential sale and other strategic alternatives for its SemiCab AI logistics business. The development could place additional investor focus on the potential value of SemiCab’s technology, customer relationships and logistics platform as the company evaluates its strategic direction.
With VIVS targeting AI-powered human drug toxicity testing, AIXI focused on enterprise cognitive intelligence, IGC approaching Alzheimer’s clinical data and RIME evaluating strategic alternatives for its AI logistics business, the four lower-priced stocks represent distinct company-specific catalysts for small-cap investors and active traders to watch.
Xiao-I (NASDAQ: AIXI) — Artificial Intelligence and Cognitive Intelligence
Xiao-I Corporation (NASDAQ: AIXI) is an artificial intelligence company focused on cognitive intelligence technologies and enterprise AI solutions. Its technology portfolio spans natural language processing, voice and image recognition, machine learning and affective computing, with applications designed to help enterprises automate operations and advance digital transformation.
With investor interest remaining elevated across the broader AI software and artificial intelligence sector, AIXI provides traders with exposure to an established developer of proprietary cognitive intelligence technologies serving a range of business applications.
https://thestreetreports.com/nasdaq-30s-vivs-...tocks-now/
August 25, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (NASDAQ: VIVS), IGC Pharma, Inc. (NYSE: IGC), Algorhythm Holdings, Inc. (NASDAQ: RIME) and Xiao-I Corporation (NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology drive trading interest.
VivoSim Labs (NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum
VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention following a research report highlighting its AI-powered drug toxicity platform and growing FDA momentum behind human-relevant New Approach Methodologies (NAMs). The company’s NAMkind™ 3D human liver and intestinal tissue models have reported approximately 91% predictive accuracy for liver toxicity and up to 96% accuracy predicting drug-induced diarrhea, while commercialization is expanding through initial China contracts and APAC distribution relationships.
VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business and recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested inflammatory bowel disease program. VivoSim has stated it remains eligible for up to an additional $45 million in potential milestone payments if specified development and commercial milestones are achieved.
IGC Pharma (NYSE: IGC) — Alzheimer’s Catalyst Approaches
IGC Pharma, Inc. (NYSE: IGC) is approaching a potentially important Alzheimer’s disease clinical catalyst after reporting Q2 2026 results that beat Street estimates and advancing its Phase 2 IGC-AD1 Alzheimer’s trial toward enrollment completion, with topline results expected in Q4 2026.
The company is also expanding its AI-enabled drug discovery capabilities. Management recently converted approximately $1.15 million of company obligations into more than 4.27 million IGC shares at $0.27 per share. Investor interest has strengthened, with shares moving from approximately $0.245 to as high as $0.308 during August, representing a roughly 25.7% increase, accompanied by elevated trading volume.
Algorhythm Holdings (NASDAQ: RIME) — Strategic Alternatives for SemiCab AI Logistics
Algorhythm Holdings, Inc. (NASDAQ: RIME) is an AI technology company whose SemiCab platform uses artificial intelligence to optimize freight networks, reduce empty truck miles, lower transportation costs and improve logistics efficiency for shippers and carriers.
Adding a new potential catalyst, Algorhythm announced on August 25, 2026 that it is pursuing a potential sale and other strategic alternatives for its SemiCab AI logistics business. The development could place additional investor focus on the potential value of SemiCab’s technology, customer relationships and logistics platform as the company evaluates its strategic direction.
With VIVS targeting AI-powered human drug toxicity testing, AIXI focused on enterprise cognitive intelligence, IGC approaching Alzheimer’s clinical data and RIME evaluating strategic alternatives for its AI logistics business, the four lower-priced stocks represent distinct company-specific catalysts for small-cap investors and active traders to watch.
Xiao-I (NASDAQ: AIXI) — Artificial Intelligence and Cognitive Intelligence
Xiao-I Corporation (NASDAQ: AIXI) is an artificial intelligence company focused on cognitive intelligence technologies and enterprise AI solutions. Its technology portfolio spans natural language processing, voice and image recognition, machine learning and affective computing, with applications designed to help enterprises automate operations and advance digital transformation.
With investor interest remaining elevated across the broader AI software and artificial intelligence sector, AIXI provides traders with exposure to an established developer of proprietary cognitive intelligence technologies serving a range of business applications.
